Manuel C. Alves Aivado
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Manuel C. Alves Aivado
Earlier roles on record: Board Member at Rein Therapeutics, Inc. (RNTX) until February 16, 2026 and CEO at Rein Therapeutics, Inc. (RNTX) until March 11, 2024. The proxy statement of Rein Therapeutics, Inc. reports total compensation of $1,331,919 for Manuel C. Alves Aivado in fiscal 2024, including a base salary of $115,960. Disclosed compensation is on record for 7 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Start not stated–2026-02-16
-
Start not stated–2024-03-11
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Rein Therapeutics, Inc. (RNTX) | M.D., Ph.D. Former President and Chief Financial Officer | $115,960 | $1,331,919 |
| 2023 | Rein Therapeutics, Inc. (RNTX) | M.D., Ph.D. Former President and Chief Financial Officer | $587,336 | $630,735 |
| 2022 | Rein Therapeutics, Inc. (RNTX) | M.D., Ph.D. Former Chief Executive Officer | $587,336 | $1,244,420 |
| 2021 | Rein Therapeutics, Inc. (RNTX) | M.D., Ph.D. Chief Executive Officer | $564,736 | $3,280,379 |
| 2020 | Rein Therapeutics, Inc. (RNTX) | M.D., Ph.D. President and Chief Executive Officer | $507,400 | $1,238,458 |
| 2019 | Rein Therapeutics, Inc. (RNTX) | M.D., Ph.D. President and Chief Executive Officer | $507,400 | $1,178,065 |
| 2018 | Rein Therapeutics, Inc. (RNTX) | M.D., President and Chief Executive Officer | $441,592 | $1,463,705 |
Recent activity
No call appearances or filed executive changes recorded yet.